Cargando…

A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam

SIMPLE SUMMARY: If reference studies can be found on the uncertainties linked to the clinical context of proton therapy, they, although equally critical, are very patchy in a preclinical context, and are specific to each beam line. This work provides the community with a complete assessment of the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bongrand, Arthur, Koumeir, Charbel, Villoing, Daphnée, Guertin, Arnaud, Haddad, Ferid, Métivier, Vincent, Poirier, Freddy, Potiron, Vincent, Servagent, Noël, Supiot, Stéphane, Delpon, Grégory, Chiavassa, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071150/
https://www.ncbi.nlm.nih.gov/pubmed/33920758
http://dx.doi.org/10.3390/cancers13081889
_version_ 1783683633376133120
author Bongrand, Arthur
Koumeir, Charbel
Villoing, Daphnée
Guertin, Arnaud
Haddad, Ferid
Métivier, Vincent
Poirier, Freddy
Potiron, Vincent
Servagent, Noël
Supiot, Stéphane
Delpon, Grégory
Chiavassa, Sophie
author_facet Bongrand, Arthur
Koumeir, Charbel
Villoing, Daphnée
Guertin, Arnaud
Haddad, Ferid
Métivier, Vincent
Poirier, Freddy
Potiron, Vincent
Servagent, Noël
Supiot, Stéphane
Delpon, Grégory
Chiavassa, Sophie
author_sort Bongrand, Arthur
collection PubMed
description SIMPLE SUMMARY: If reference studies can be found on the uncertainties linked to the clinical context of proton therapy, they, although equally critical, are very patchy in a preclinical context, and are specific to each beam line. This work provides the community with a complete assessment of the sources of uncertainties for a preclinical proton beam line. This aims to ensure that, in this line, the biological results observed and the dose–response relationships are obtained without any bias. Despite being specific to a preclinical line, the results presented here can be transposed to other types of proton preclinical facilities, and thus allow us to effectively compare them to one another. ABSTRACT: Proton therapy (PRT) is an irradiation technique that aims at limiting normal tissue damage while maintaining the tumor response. To study its specificities, the ARRONAX cyclotron is currently developing a preclinical structure compatible with biological experiments. A prerequisite is to identify and control uncertainties on the ARRONAX beamline, which can lead to significant biases in the observed biological results and dose–response relationships, as for any facility. This paper summarizes and quantifies the impact of uncertainty on proton range, absorbed dose, and dose homogeneity in a preclinical context of cell or small animal irradiation on the Bragg curve, using Monte Carlo simulations. All possible sources of uncertainty were investigated and discussed independently. Those with a significant impact were identified, and protocols were established to reduce their consequences. Overall, the uncertainties evaluated were similar to those from clinical practice and are considered compatible with the performance of radiobiological experiments, as well as the study of dose–response relationships on this proton beam. Another conclusion of this study is that Monte Carlo simulations can be used to help build preclinical lines in other setups.
format Online
Article
Text
id pubmed-8071150
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80711502021-04-26 A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam Bongrand, Arthur Koumeir, Charbel Villoing, Daphnée Guertin, Arnaud Haddad, Ferid Métivier, Vincent Poirier, Freddy Potiron, Vincent Servagent, Noël Supiot, Stéphane Delpon, Grégory Chiavassa, Sophie Cancers (Basel) Article SIMPLE SUMMARY: If reference studies can be found on the uncertainties linked to the clinical context of proton therapy, they, although equally critical, are very patchy in a preclinical context, and are specific to each beam line. This work provides the community with a complete assessment of the sources of uncertainties for a preclinical proton beam line. This aims to ensure that, in this line, the biological results observed and the dose–response relationships are obtained without any bias. Despite being specific to a preclinical line, the results presented here can be transposed to other types of proton preclinical facilities, and thus allow us to effectively compare them to one another. ABSTRACT: Proton therapy (PRT) is an irradiation technique that aims at limiting normal tissue damage while maintaining the tumor response. To study its specificities, the ARRONAX cyclotron is currently developing a preclinical structure compatible with biological experiments. A prerequisite is to identify and control uncertainties on the ARRONAX beamline, which can lead to significant biases in the observed biological results and dose–response relationships, as for any facility. This paper summarizes and quantifies the impact of uncertainty on proton range, absorbed dose, and dose homogeneity in a preclinical context of cell or small animal irradiation on the Bragg curve, using Monte Carlo simulations. All possible sources of uncertainty were investigated and discussed independently. Those with a significant impact were identified, and protocols were established to reduce their consequences. Overall, the uncertainties evaluated were similar to those from clinical practice and are considered compatible with the performance of radiobiological experiments, as well as the study of dose–response relationships on this proton beam. Another conclusion of this study is that Monte Carlo simulations can be used to help build preclinical lines in other setups. MDPI 2021-04-15 /pmc/articles/PMC8071150/ /pubmed/33920758 http://dx.doi.org/10.3390/cancers13081889 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bongrand, Arthur
Koumeir, Charbel
Villoing, Daphnée
Guertin, Arnaud
Haddad, Ferid
Métivier, Vincent
Poirier, Freddy
Potiron, Vincent
Servagent, Noël
Supiot, Stéphane
Delpon, Grégory
Chiavassa, Sophie
A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam
title A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam
title_full A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam
title_fullStr A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam
title_full_unstemmed A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam
title_short A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam
title_sort monte carlo determination of dose and range uncertainties for preclinical studies with a proton beam
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071150/
https://www.ncbi.nlm.nih.gov/pubmed/33920758
http://dx.doi.org/10.3390/cancers13081889
work_keys_str_mv AT bongrandarthur amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT koumeircharbel amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT villoingdaphnee amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT guertinarnaud amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT haddadferid amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT metiviervincent amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT poirierfreddy amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT potironvincent amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT servagentnoel amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT supiotstephane amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT delpongregory amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT chiavassasophie amontecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT bongrandarthur montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT koumeircharbel montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT villoingdaphnee montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT guertinarnaud montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT haddadferid montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT metiviervincent montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT poirierfreddy montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT potironvincent montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT servagentnoel montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT supiotstephane montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT delpongregory montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam
AT chiavassasophie montecarlodeterminationofdoseandrangeuncertaintiesforpreclinicalstudieswithaprotonbeam